Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDC Panel Okays Use Of Omicron Bivalent COVID-19 Vaccines Despite Lack Of Clinical Data

Executive Summary

One member says the vote was premature, but others conclude extrapolation of clinical data from another vaccine was sufficient given similar experience with flu vaccines and the potential to save thousands of lives.

You may also be interested in...

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.

Novavax Hopes COVID-19/Flu Vaccine Combo Can Help It Keep Up With mRNA Leaders

Novavax recently slashed its revenues forecasts, but is hoping a two-in-one COVID-19 and flu combination could help it carve out space in the post-pandemic market.

COVID-19 Vaccine Manufacturers Urged To Make Labeling Changes To Avoid Administration Errors

CDC advisory panel members voice concerns about mix-ups in the administration of COVID-19 vaccines. Pfizer’s bivalent and monovalent vaccines have the same gray cap while Moderna has different colored caps for its two versions.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts